动脉内注射贝伐单抗治疗复发性胶质母细胞瘤的长期疗效

Long-term benefit of intra-arterial bevacizumab for recurrent glioblastoma.

作者信息

Alter Rachel A, White Timothy G, Fanous Andrew A, Chakraborty Shamik, Filippi Christopher G, Pisapia David J, Tsiouris Apostolos John, Boockvar John A

机构信息

Brain Tumor Center, Department of Neurosurgery, Lenox Hill Hospital, New York, NY, USA.

Department of Neurosurgery, Hofstra Northwell School of Medicine, Hempstead, NY, USA.

出版信息

J Exp Ther Oncol. 2017 May;12(1):67-71.

PMID:28472567

Abstract

Standard treatment for recurrent GBM is not yet established. We present a case demonstrating the benefit of intra-arterial (IA) bevacizumab with blood brain barrier disruption (BBBD) for the treatment of recurrent GBM. A 31 year-old man diagnosed with GBM, following primary resection, received temozolomide. After a second resection, he received one dose of IA bevacizumab with BBBD using mannitol, preventing regrowth for 2.5 years. Following tumor regrowth, the patient received another dose of IA bevacizumab with BBBD, which has prevented regrowth for another year.

摘要

复发性胶质母细胞瘤的标准治疗方法尚未确立。我们报告了一例病例，该病例显示动脉内（IA）注射贝伐单抗并联合血脑屏障破坏（BBBD）治疗复发性胶质母细胞瘤的益处。一名31岁男性被诊断为胶质母细胞瘤，在初次切除术后接受了替莫唑胺治疗。二次切除术后，他使用甘露醇接受了一剂IA贝伐单抗联合BBBD治疗，肿瘤生长被抑制了2.5年。肿瘤复发后，患者又接受了一剂IA贝伐单抗联合BBBD治疗，肿瘤生长又被抑制了一年。